FOCUSED ON LIFE

“My founding vision for Nuvation Bio is to develop and commercialize new generations of oncology medicines that will meaningfully improve the lives of patients by addressing the drug resistance or limited efficacy of current therapies, while reducing side effects and preserving quality of life. We are focused on developing and commercializing novel therapies for the most difficult-to-treat cancers, specifically targeting indications for which conventional therapies have failed. To that end, we are developing a deep pipeline of differentiated and novel therapeutic candidates that target some of the most critical pathways that cancer cells use to grow. The data generated to date from clinical and preclinical studies demonstrate the potential of our candidates to significantly improve outcomes over current standards of care.”

– David Hung, M.D., Founder, President, and Chief Executive Officer